Agenus to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
September 08 2015 - 10:00AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immunology company developing
innovative treatments for cancers and other diseases, today
announced that the Company will present at the Rodman & Renshaw
17th Annual Global Investment Conference on Wednesday, September
9th at 10:00 a.m. Eastern Time. The conference will take place at
the St. Regis Hotel in New York City.
Webcast Information
The live and archived webcast of the presentation will be
accessible from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before each event to
ensure a timely connection. The archived replay will be available
on the Agenus website for one month following the conference.
About Agenus
Agenus is an immunology company engaged in the discovery and
development of novel checkpoint modulators, vaccines and adjuvants
to treat cancer and other diseases. Using its proprietary platforms
Retrocyte Display™ and SECANT®, the Company is discovering and
developing novel antibodies to target GITR, OX40, CTLA-4, LAG-3,
TIM-3, PD-1 and other undisclosed checkpoints in partnered and
internal programs. Agenus’ heat shock protein vaccine, Prophage,
has successfully completed Phase 2 studies in newly diagnosed
glioblastoma multiforme. The Company’s QS-21 Stimulon® adjuvant is
extensively partnered with GlaxoSmithKline and Janssen Sciences
Ireland UC, and two vaccine candidates containing QS-21 have
successfully completed Phase 3 trials. For more information, please
visit www.agenusbio.com, or follow the company on Twitter
@Agenus_Bio; information that may be important to investors will be
routinely posted in these locations.
Forward-Looking Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the expected
benefit from GSK’s Mosquirix™ vaccine, the potential milestone and
royalties payable to Agenus and the Company’s potential to create
best-in-class combination therapies for treating patients with
cancer. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of Agenus’ Prospectus
Supplement filed with the Securities and Exchange Commission on May
21, 2015. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150908006062/en/
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney, 212-600-1902andrea@argotpartners.comorJamie
Maarten, 212-600-1902jamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024